LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 101 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $62,506 | -27.4% | 52,971 | -13.2% | 0.00% | – |
Q2 2023 | $86,063 | +1663.6% | 61,037 | +1776.3% | 0.00% | – |
Q1 2023 | $4,880 | -60.3% | 3,253 | -69.0% | 0.00% | – |
Q4 2022 | $12,291 | +1129.1% | 10,506 | +706.9% | 0.00% | – |
Q3 2022 | $1,000 | -94.4% | 1,302 | -88.6% | 0.00% | – |
Q2 2022 | $18,000 | +1700.0% | 11,420 | +1177.4% | 0.00% | – |
Q1 2022 | $1,000 | -99.0% | 894 | -97.8% | 0.00% | – |
Q4 2021 | $97,000 | -81.5% | 39,932 | -80.8% | 0.00% | – |
Q3 2021 | $523,000 | +3923.1% | 207,702 | +4468.9% | 0.00% | – |
Q2 2021 | $13,000 | -23.5% | 4,546 | -38.0% | 0.00% | – |
Q1 2021 | $17,000 | -61.4% | 7,337 | -70.2% | 0.00% | – |
Q4 2020 | $44,000 | +4300.0% | 24,602 | +2098.6% | 0.00% | – |
Q3 2020 | $1,000 | 0.0% | 1,119 | -17.5% | 0.00% | – |
Q2 2020 | $1,000 | -98.3% | 1,357 | -98.1% | 0.00% | – |
Q1 2020 | $59,000 | -57.6% | 70,916 | -54.5% | 0.00% | – |
Q4 2019 | $139,000 | +69.5% | 155,913 | +86.6% | 0.00% | – |
Q3 2019 | $82,000 | – | 83,573 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |